Patrizia Cavazzoni | |
|---|---|
 Official FDA Portrait | |
| Director of the Center for Drug Evaluation and Research[1] | |
| Assumed office April 12, 2021 Acting: May 2020 – April 2021 | |
| Preceded by | Janet Woodcock |
| Acting Principal Deputy Commissioner of Food and Drugs[2] | |
| In office January 2019 – February 2019 | |
| Succeeded by | Amy Abernethy |
| Deputy Center Director for Operations of the FDA Center for Drug Evaluation and Research | |
| In office January 2018 – May 2020 | |
| Personal details | |
| Education | McGill University (MD)[2] |
Patrizia Cavazzoni is the director of the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER). Prior to this position she worked at Pfizer and had been a psychiatrist. She resigned from FDA on January 10, 2025, ten days before Donald Trump took office.[3]
- ^ "CDER Leadership Bios". U.S. Food and Drug Administration. April 12, 2021.
- ^ a b "Patrizia Cavazzoni M.D." U.S. Food and Drug Administration. April 12, 2021.
- ^ Feuerstein, Lizzy Lawrence, Adam (2025-01-10). "Patrizia Cavazzoni, head of FDA's drug center, to leave the agency". STAT. Retrieved 2025-01-10.
{{cite web}}: CS1 maint: multiple names: authors list (link)